Pelthos Therapeutics Inc. (PTHS)
| Market Cap | 92.00M +1,295.6% |
| Revenue (ttm) | 27.70M |
| Net Income | -51.59M |
| EPS | -20.19 |
| Shares Out | 3.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,394 |
| Open | 26.05 |
| Previous Close | 25.80 |
| Day's Range | 25.80 - 27.10 |
| 52-Week Range | 9.00 - 54.29 |
| Beta | 3.33 |
| Analysts | Strong Buy |
| Price Target | 57.71 (+118.02%) |
| Earnings Date | May 14, 2026 |
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $57.71, which is an increase of 118.02% from the latest price.
News
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics NYSEAMERICAN: PTHS reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment's third full quarter since launch, exe...
Pelthos Therapeutics price target raised to $66 from $62 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $66 from $62 and keeps an Outperform rating on the shares after the company reported results…
Pelthos Therapeutics reports Q1 EPS ($3.58), consensus ($3.09)
Reports Q1 revenue $10.91M, consensus $10.44M. Scott Plesha, CEO of Pelthos, stated, “In the first quarter of 2026, we continued to build momentum for ZELSUVMI, driven by the expansion of…
Pelthos Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth and prescription gains for ZELSUVMI, supported by sales force expansion and a major PBM contract. Net loss narrowed, working capital improved, and launches for Xepi and Xeglyze are on track for 2027. Medicaid coverage for ZELSUVMI reached 99%.
Pelthos Therapeutics Earnings release: Q1 2026
Pelthos Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Pelthos Therapeutics Quarterly report: Q1 2026
Pelthos Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
ZELSUVMI ® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 uniq...
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics Slides: Corporate presentation
Pelthos Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO
Pelthos Therapeutics (PTHS) announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos’ CFO since July 2025. Gay has served as…
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Pelthos is emerging as a commercial launch story, with early script trends indicating...
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target
Pelthos Therapeutics doses first patient in CT2000 trial
Pelthos Therapeutics (PTHS) announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos’ subsidiary Channel Pharmac...
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease
Pelthos Therapeutics Transcript: The 38th Annual Roth Conference
Pelthos has rapidly grown ZELSUVMI prescriptions and revenue, with strong payer coverage and a robust cash position. Upcoming launches of Xepi and Xeglyze will leverage existing sales channels, while patent protection and proprietary manufacturing support long-term growth.
Pelthos Therapeutics Inc trading resumes
11:13 EDT Pelthos Therapeutics (PTHS) Inc trading resumes
Pelthos Therapeutics Inc trading halted, volatility trading pause
11:08 EDT Pelthos Therapeutics (PTHS) Inc trading halted, volatility trading pause
Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $62 from $60 and keeps an Outperform rating on the shares after the company reported year-end…
Pelthos Therapeutics Earnings Call Transcript: Q4 2025
Q4 2025 saw strong revenue growth and reduced losses, driven by ZELSUVMI's rapid uptake and expanded coverage. Two FDA-approved product acquisitions and new financing position the company for continued growth and expected profitability by year-end 2026.
Pelthos Therapeutics Annual report: Q4 2025
Pelthos Therapeutics has published its Q4 2025 annual report on March 19, 2026.
Pelthos Therapeutics Earnings release: Q4 2025
Pelthos Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year
Reports Q4 Zelsuvmi revenue $9.1M vs. $7.1M vs. last year. CEO Scott Plesha commented, “We are delighted with the growth of Zelsuvmi in our second quarter of commercialization despite the…
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...